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SHORT COMMUNICATION
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Summary Nerve growth factor (NGF) administration to athymic mice with transplanted human
bromocriptine-resistant prolactinoma, results in the expression of dopamine D-2 receptors in the tumour and
restores sensitivity to subsequent treatment with bromocriptine, which then produces normalisation of plasma
prolactin and tumour regression. Sequential administration of NGF and bromocriptine thus may be a
promising therapy for patients refractory to bromocriptine.
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Prolactin (PRL)-secreting pituitary adenomas are the most
frequent neoplasm in the human pituitary and range in size
from small microadenomas, i.e. tumours smaller than 1 cm in
maximal diameter, to large extrasellar macroadenomas with
signs of local invasiveness (Davis et al., 1990; Cunnah and
Besser, 1991). The symptoms of prolactinomas are mostly
related to hyperprolactinaemia, but local symptoms, partic-
ularly headache, visual field defects and, more rarely, symp-
toms of cavernous sinus compression may occur when
adenomas are large (Davis et al., 1990; Cunnah and Besser,
1991).
The turning point in the management of PRL-secreting
tumours was the discovery that they express D-2 receptors
for dopamine (DA), the physiological inhibitor of PRL secre-
tion (Wood et al., 1991). This finding led to the development
of the D-2 DA receptor agonist bromocriptine as the most
effective pharmacological tool for therapy of prolactinomas
(Cunnah and Besser, 1991; Wood et al., 1991).
This therapy, however, is not invariably effective; 10-15%
of patients are, in fact, non-responders and require pituitary
surgery or external irradiation (Cunnah and Besser, 1991;
Wood et al., 1991). However, these are rarely successful in
patients with extrasellar and/or invasive tumours (Schlechte
et al., 1986). Management of such non-responding patients
thus remains a therapeutical challenge.
The major biochemical defect contributing to DA agonist
resistance in prolactinomas is decreased density of D-2 recep-
tors (Pellegrini et al., 1989). In a recent study with human
prolactinomas we found that the tumours clinically resistant
to bromocriptine do not express D-2 receptors for DA (Mis-
sale et al., 1993). However, these tumours do express recep-
tors for nerve growth factor (NGF), a neurotrophic protein
that promotes growth, differentiation and survival of specific
populations of neurons (Levi-Montalcini, 1987) and that also
exerts differentiating effects on cells of endocrine origin (Mis-
sale et al., 1994). Short-term exposure of bromocriptine-
resistant prolactinomas to NGF, both in vitro and in vivo,
results in their long lasting conversion into lactotroph-like
cells that once again express the D-2 receptor protein (Mis-
sale et al., 1993). The possibility thus exists that short-term
treatment with NGF might restore responsiveness to bromo-
criptine therapy in patients resistant to dopaminergic treat-
ment.
In the present study, we investigated whether or not
sequential administrations of NGF and bfomocriptine were
an effective therapy for athymic mice transplanted with
bromocriptine-resistant human prolactinomas.
Cells obtained from one human bromocriptine-resistant
prolactinoma were transplanted, s.c. (107 cells per mouse)
into 24 Nu/Nu mice (20 g body weight; Charles River
Breeding Laboratories). After development of tumours of
15 ± 1 mm3, the mice were divided into four groups. Two
groups were treated with saline (n = 12) and two groups with
NGF (1 jigg-' body weight, i.v.; n = 12) once a day for 5
consecutive days. Fifteen days after the last NGF administra-
tion one subgroup of controls (n = 6) and one subgroup of
NGF-treated mice (n = 6) were injected with bromocriptine
to determine plasma PRL levels. Tumour size was measured
before and after NGF administration during a 40 day follow-
up period.
Figure 1 shows the sizes of the transplanted tumours in
saline- and NGF-treated mice at the end of the follow-up.
Tumours of 600 ± 40 mm3 were detectable in saline-treated
mice (Figure la). The 5 day NGF treatment inhibited
tumour growth remarkably so that the tumours grew to only
72 ± 1Omm3 (Figure lb). The complete tumour growth
curves for saline- and NGF-treated mice are shown in Figure
2a. The effect of NGF was already evident at the end of
treatment and was even more significant after prolonged
follow-up. None of the 12 mice injected with NGF died
during treatment. In addition, no important side-effects were
noted following NGF administration.
Bromocriptine did not modify tumour growth in saline-
treated mice (Figure 2b). However, the drug recovered its full
activity when injected into mice previously treated with
NGF. As a result of bromocriptine administration, the
tumour size progressively decreased, completely regressing
within 11 days (Figure 2b). Tumours did not reappear after
bromocriptine therapy was discontinued (Figures lc and 2b).
Mice transplanted with prolactinomas had higher plasma
PRL levels than normal animals. Analysis of blood samples
obtained immediately before and 2 days after beginning
bromocriptine administration revealed bromocriptine-induced
normalisation of PRL levels in NGF-treated animals (650
±52ngml-' before bromocriptine and 195±15ngml-'
after bromocriptine administration). Similar results were
obtained with two additional human tumours.
Bromocriptine thus recovered both its PRL-suppressing
and antiproliferative effects in nude mice grafted with DA-
insensitive tumours when they had been pretreated with
NGF.
Short-term treatment with NGF thus induces long-lasting
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Figure I Appearance of human bromocriptine-resistant prolac-
tinomas in athymic mice. Nu/Nu mice transplanted with
bromocriptine-resistant human prolactinomas were treated with
saline or NGF ( jgg-g body weight, i.v.) for 5 days. Fifteen
days after the last NGF administration one group of NGF-
treated mice was injected with bromocriptine (0.01 lgg-g body
weight; i.p.) for 15 days. (a) Tumours in anesthetised saline-
treated mice 40 days after the last saline administration. (b)
Tumours in anesthetised NGF-treated nude mice 40 days after
the last NGF administration. (c) Regression of tumours by
bromocriptine in nude mice pretreated with NGF.
600 NGF or
saline
,; 500
E
E
, 300
0
E
F 200
100*
0L
1 11 17 21 26 36 46
Time (days)
b
600 ~~~~Bromocriptine NGF or __500 saline
E 400 E
Q' 300
200
0
E
= 100
I-
50*
0 A. ~ ~ *
0 r- Fr
1 11 16 21 26 31 36 41 46
Time (days)
Figure 2 Effects of bromocriptine on tumour growth in saline-
and NGF-treated nude mice. Mice transplanted with bromo-
criptine-resistant human prolactinomas were treated with saline
or NGF ( llg g-' body weight, i.v.) for 5 days and then with
bromocriptine (0.01 llg g-' body weight; i.p.) for 15 days. (a)
tumour growth curves in saline (0) and NGF-treated (@) nude
mice. From days 36 to 46 tumours completely regressed. Points
are the means ± s.e.m. of six mice in each group. *P<O0.00 vs
saline-treated mice; Student's t-test. Statistical analysis was app- lied to points corresponding to individual times.
and full sensitivity to subsequent therapy with bromocriptine in mice transplanted with DA-resistant human prolac- tinomas. Remarkably, the effects of bromocriptine in this
model are similar to those observed in patients with prolac- tinomas sensitive to the dopaminergic therapy (Cunnah and Besser, 1991; Wood et al., 1991).
The present data, obtained in a proper animal model, show the first successful pharmacological treatment of DA- resistant human macroprolactinomas and open the way to development of a new, promising therapy for non-responding patients. It is important that only a few doses of NGF have
to be administered to prime refractory patients to respond to bromocriptine, since there are fewer side-effects when NGF is
administered acutely. It has been shown, in fact, that a single administration of NGF to healthy human volunteers is not life-threatening and induces only transient, mild to moderate
muscle pain (Petty et al., 1994).
Therefore, sequential therapy with NGF and bromocrip- tine appears to be a potential and promising alternative to neurosurgical intervention for patients with DA-resistant prolactinomas.
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